[SCHEDULE 13D/A] BridgeBio Pharma, Inc. SEC Filing

Rhea-AI Filing Summary

On 06/27/2025, BridgeBio Pharma (BBIO) received a Form 4 from Viking Global Investors LP and affiliated Viking funds disclosing the open-market sale of 3,500,000 common shares at an indicated price of $44.00. The transaction code “S” confirms a disposition. Following the sale, the Viking entities collectively hold 18,555,375 BBIO shares, down roughly 16% from their prior position (~22.1 million shares), yet they remain a statutory 10 % beneficial owner. No derivative securities were involved. The filing consolidates ownership across VGEM, VLFM and the Opportunities Fund, with executive committee members Andreas Halvorsen, David C. Ott and Rose S. Shabet listed as indirect beneficial owners. The group expressly disclaims beneficial ownership beyond pecuniary interest.

Positive

• None.

Negative

• Viking Global Investors sold 3.5 million BBIO shares (≈16 % of its prior stake) at $44, signaling diminished short-term conviction.

Insights

Securities Analyst

TL;DR – 16 % stake reduction by Viking is a moderately negative signal but they retain a large position.

Viking Global, historically a long-term healthcare investor, cut its BBIO exposure by 3.5 million shares at $44, implying ~$154 million in proceeds. Although the group still holds 18.6 million shares, the size of the sale—roughly two weeks of average BBIO trading volume—may create short-term technical pressure and can be interpreted as profit-taking after the stock’s appreciation. The lack of accompanying derivative hedges suggests a straightforward reduction rather than a complex restructuring. Overall impact: negative, but tempered by Viking’s continued 10 % ownership, which signals residual conviction.

Corporate Governance Specialist

TL;DR – High-profile insider sale raises governance questions on timing but retains board-level influence.

The multi-entity filing highlights Viking’s intricate fund structure and continued coordinated control. Disclaimers limit legal liability; however, investors often view insider disposals by a controlling shareholder skeptically, especially when sizeable. Remaining above the 10 % threshold preserves voting influence, suggesting governance dynamics at BridgeBio stay largely unchanged. Impact is moderately negative for sentiment, not for control.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 7)

BridgeBio Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

10806X102

(CUSIP Number)

Matthew Bloom
General Counsel, 600 Washington Boulevard, Floor 11
Stamford, CT, 06901
(212) 672-7059

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

06/27/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

VIKING GLOBAL INVESTORS LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.8 %

14

Type of Reporting Person (See Instructions)

PN

Comment for Type of Reporting Person:

All share percentage calculations in this Amendment No. 7 to the Schedule 13D are based on 189,880,720 shares of Common Stock, par value $0.001 per share, of BridgeBio Pharma, Inc. (the "Issuer") outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Securities and Exchange Commission (the "Commission") on April 29, 2025.

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

VIKING GLOBAL PERFORMANCE LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 339,695.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 339,695.00

11

Aggregate amount beneficially owned by each reporting person

339,695.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Equities II LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 6,794.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 6,794.00

11

Aggregate amount beneficially owned by each reporting person

6,794.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Equities Master Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 332,901.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 332,901.00

11

Aggregate amount beneficially owned by each reporting person

332,901.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.2 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Long Fund GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 118,214.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 118,214.00

11

Aggregate amount beneficially owned by each reporting person

118,214.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Long Fund Master Ltd.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 118,214.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 118,214.00

11

Aggregate amount beneficially owned by each reporting person

118,214.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.1 %

14

Type of Reporting Person (See Instructions)

CO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Parent GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,145,011.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,145,011.00

11

Aggregate amount beneficially owned by each reporting person

18,145,011.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,145,011.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,145,011.00

11

Aggregate amount beneficially owned by each reporting person

18,145,011.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Portfolio GP LLC

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,145,011.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,145,011.00

11

Aggregate amount beneficially owned by each reporting person

18,145,011.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.6 %

14

Type of Reporting Person (See Instructions)

OO

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Illiquid Investments Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,089,980.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,089,980.00

11

Aggregate amount beneficially owned by each reporting person

18,089,980.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.5 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Viking Global Opportunities Liquid Portfolio Sub-Master LP

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 55,031.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 55,031.00

11

Aggregate amount beneficially owned by each reporting person

55,031.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

0.03 %

14

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

HALVORSEN OLE ANDREAS

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

NORWAY

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Ott David C.

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

CUSIP No. 10806X102

1

Name of reporting person

Shabet Rose Sharon

2

Check the appropriate box if a member of a Group (See Instructions)

(a)
(b)

3

SEC use only

4

Source of funds (See Instructions)

OO

5

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

6

Citizenship or place of organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

7	Sole Voting Power 0.00
8	Shared Voting Power 18,602,920.00
9	Sole Dispositive Power 0.00
10	Shared Dispositive Power 18,602,920.00

11

Aggregate amount beneficially owned by each reporting person

18,602,920.00

12

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13

Percent of class represented by amount in Row (11)

9.8 %

14

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13D

Item 1.	Security and Issuer
(a)	Title of Class of Securities: Common Stock, par value $0.001 per share
(b)	Name of Issuer: BridgeBio Pharma, Inc.
(c)	Address of Issuer's Principal Executive Offices: 3160 Porter Drive, Suite 250, Palo Alto, CALIFORNIA , 94304.
Item 1 Comment: Pursuant to Rule 13d-2 under the Securities Exchange Act of 1934, as amended, this Amendment No. 7 to the Schedule 13D ("Amendment No. 7") amends certain items of the Schedule 13D filed with the Commission on July 8, 2019, as amended and supplemented by Amendment No. 1 filed with the Commission on July 19, 2023, Amendment No. 2 filed with the Commission on November 22, 2023, Amendment No. 3 filed with the Commission on August 20, 2024, Amendment No. 4 filed with the Commission on November 6, 2024, Amendment No. 5 filed with the Commission on January 31, 2025 and Amendment No. 6 filed with the Commission on March 12, 2025 (collectively, the "Schedule 13D") relating to the Common Stock, par value $0.001 per share (the "Common Stock") of BridgeBio Pharma, Inc., a Delaware corporation (the "Issuer"). All capitalized terms contained herein but not otherwise defined shall have the meanings ascribed to such terms in the Schedule 13D.
Item 2.	Identity and Background
(a)	Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows: This Schedule 13D is being filed jointly on behalf of Viking Global Investors LP("VGI"), Viking Global Performance LLC ("VGP"), Viking Global Equities II LP ("VGEII"), Viking Global Equities Master Ltd. ("VGEM"), Viking Long Fund GP LLC ("VLFGP"), Viking Long Fund Master Ltd. ("VLFM"), Viking Global Opportunities Parent GP LLC ("Opportunities Parent"), Viking Global Opportunities GP LLC ("Opportunities GP"), Viking Global Opportunities Portfolio GP LLC ("Opportunities Portfolio GP"), Viking Global Opportunities Illiquid Investments Sub-Master LP ("Opportunities Fund"), Viking Global Opportunities Liquid Portfolio Sub-Master LP ("VGOL", and, together with VGEII, VGEM, VLFM and Opportunities Fund, the "Funds"), O. Andreas Halvorsen, David C. Ott, and Rose S. Shabet, (each, a "Reporting Person", and, collectively, the "Reporting Persons"). The Reporting Persons have entered into a joint filing agreement, dated as of the date hereof, a copy of which is filed herewith as Exhibit 99.6.
(b)	The business address of each of the Reporting Persons is: 600 Washington Boulevard, Floor 11, Stamford, Connecticut 06901.
(c)	The principal business of VGI is to provide managerial services to related entities engaged in making or recommending investments in securities of public and private companies. The principal business of each of VGP, VLFGP, Opportunities Parent, Opportunities GP and Opportunities Portfolio GP is to serve as the general partner, sole member or investment manager of related entities engaged in making or recommending investments in securities of public and private companies. The principal business of each of the Funds is to engage in making investments in securities of public and private companies. The present principal occupation of O. Andreas Halvorsen is Chief Executive Officer of VGI. The present principal occupation of David C. Ott is Advisory Director of VGI. The present principal occupation of Rose S. Shabet is Chief Operating Officer of VGI.
(d)	During the last five years, none of the Reporting Persons has been convicted in any criminal proceeding (excluding traffic violations or similar misdemeanors).
(e)	During the last five years, none of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.
(f)	VGI and VGEII are Delaware limited partnerships; VGP, VLFGP, Opportunities Parent, Opportunities GP and Opportunities Portfolio GP are Delaware limited liability companies; VGEM and VLFM are Cayman Islands exempted companies; Opportunities Fund and VGOL are Cayman Islands exempted limited partnerships; O. Andreas Halvorsen is a citizen of Norway; and David C. Ott and Rose S. Shabet are citizens of the United States.
Item 3.	Source and Amount of Funds or Other Consideration
	Item 3 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 7 is incorporated by reference herein. The source of funds used in making the purchases is the capital invested in the Funds by their investors.
Item 4.	Purpose of Transaction
	Item 4 of the Schedule 13D is hereby amended and supplemented as follows: The response to Item 5(c) of this Amendment No. 7 is incorporated by reference herein.
Item 5.	Interest in Securities of the Issuer
(a)	Item 5(a) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference. The percentage of outstanding shares of Common Stock that may be deemed to be beneficially owned by each Reporting Person is set forth on Line 13 of such Reporting Person's cover sheet. Such percentage was calculated for each Reporting Person based on 189,880,720 shares of Common Stock outstanding as of April 22, 2025, as reported in the Issuer's quarterly report on Form 10-Q filed with the Commission on April 29, 2025. VGEII has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEII. VGEM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VGP, and by VGI, an affiliate of VGP, which provides managerial services to VGEM. Viking Global Equities LP (a Delaware limited partnership) and Viking Global Equities III Ltd. (a Cayman Islands exempted company), through its investment in VGE III Portfolio Ltd. (a Cayman Islands exempted company), invest substantially all of their assets through VGEM. VLFM has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its investment manager, VLFGP, and by VGI, an affiliate of VLFGP, which provides managerial services to VLFM. Viking Long Fund LP (a Delaware limited partnership) and Viking Long Fund III Ltd. (a Cayman Islands exempted company), through its investment in Viking Long Fund Intermediate L.P. (a Cayman Islands limited partnership), invest substantially all of their assets through VLFM. Opportunities Fund has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to Opportunities Fund. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through Opportunities Fund. VGOL has the authority to dispose of and vote the shares of Common Stock directly owned by it, which power may be exercised by its general partner, Opportunities Portfolio GP, and by VGI, an affiliate of Opportunities Portfolio GP, which provides managerial services to VGOL. Viking Global Opportunities LP (a Delaware limited partnership) and Viking Global Opportunities III LP (a Cayman Islands exempted limited partnership), through its investment in Viking Global Opportunities Intermediate LP (a Cayman Islands exempted limited partnership), invest substantially all of their assets in Viking Global Opportunities Master LP (a Cayman Islands exempted limited partnership), which in turn invests through VGOL. VGI provides managerial services to the Funds. VGI has the power to direct the vote and disposition of the shares of Common Stock directly held by the Funds. Accordingly, VGI may be deemed to have beneficial ownership over any shares of Common Stock directly owned by the Funds. VGP serves as the general partner of VGEII and the investment manager to VGEM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VGEII and VGEM. Accordingly, VGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VGEII and VGEM. VLFGP serves as the investment manager of VLFM and has the power to direct the vote and disposition of the shares of Common Stock directly held by VLFM. Accordingly, VLFGP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by VLFM. Opportunities Portfolio GP serves as the general partner of each of Opportunities Fund and VGOL and has the power to direct the vote and disposition of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities Portfolio GP may be deemed to have beneficial ownership over any shares of Common Stock directly owned by Opportunities Fund and VGOL. Opportunities GP serves as the sole member of Opportunities Portfolio GP and has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities GP may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities Portfolio GP, consisting of any shares of Common Stock directly owned by Opportunities Fund and VGOL. Opportunities Parent serves as the sole member of Opportunities GP, which has the power to direct the vote and disposition of the shares of Common Stock controlled by Opportunities Portfolio GP, which consists of the shares of Common Stock directly held by Opportunities Fund and VGOL. Accordingly, Opportunities Parent may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by Opportunities GP, consisting of any shares of Common Stock directly owned by Opportunities Fund and VGOL. Messrs. Halvorsen and Ott and Ms. Shabet, as Executive Committee Members of Viking Global Partners LLC (the general partner of VGI), VGP, VLFGP and Opportunities Parent, have shared authority to direct the voting and disposition of the shares of Common Stock beneficially owned by VGI, VGP, VLFGP and Opportunities Parent. Accordingly, each of Messrs. Halvorsen and Ott and Ms. Shabet may be deemed to have beneficial ownership over any shares of Common Stock deemed beneficially owned by VGI, VGP, VLFGP, Opportunities Parent and VGOL. Except as disclosed in this Amendment No. 7, none of the Reporting Persons beneficially owns any shares of Common Stock or has the right to acquire any shares of Common Stock. Except as disclosed in this Amendment No. 7, none of the Reporting Persons presently has the power to vote or to direct the vote or to dispose or direct the disposition of any shares of Common Stock that such Reporting Person may be deemed to beneficially own.
(b)	Item 5(b) of the Schedule 13D is hereby amended and supplemented as follows: The information contained on each of the cover pages of this Schedule 13D and the information set forth or incorporated in Items 2, 3, 4 and 6 are hereby incorporated herein by reference.
(c)	Item 5(c) of the Schedule 13D is hereby amended and supplemented as follows: Except for the transactions listed in Exhibit 99.7 of this Amendment No. 7, the Reporting Persons have not effected any transactions in the Common Stock during the past 60 days.
Item 7.	Material to be Filed as Exhibits.
	Item 7 of the Schedule 13D is hereby amended and supplemented as follows: Exhibit 99.6 - Joint Filing Agreement, dated as of July 1, 2025, among the Reporting Persons Exhibit 99.7 - Schedule of Transactions

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

VIKING GLOBAL INVESTORS LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL INVESTORS LP (1)(2)(3)
Date:	07/01/2025

VIKING GLOBAL PERFORMANCE LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of VIKING GLOBAL PERFORMANCE LLC (1)(2)(3)
Date:	07/01/2025

Viking Global Equities II LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Equities II LP (1)(2)(3)
Date:	07/01/2025

Viking Global Equities Master Ltd.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Equities Master Ltd. (1)(2)(3)
Date:	07/01/2025

Viking Long Fund GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Long Fund GP LLC (1)(2)(3)
Date:	07/01/2025

Viking Long Fund Master Ltd.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Long Fund Master Ltd. (1)(2)(3)
Date:	07/01/2025

Viking Global Opportunities Parent GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Parent GP LLC (1)(2)(3)
Date:	07/01/2025

Viking Global Opportunities GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities GP LLC (1)(2)(3)
Date:	07/01/2025

Viking Global Opportunities Portfolio GP LLC

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Portfolio GP LLC (1)(2)(3)
Date:	07/01/2025

Viking Global Opportunities Illiquid Investments Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Illiquid Investments Sub-Master LP (1)(2)(3)
Date:	07/01/2025

Viking Global Opportunities Liquid Portfolio Sub-Master LP

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Viking Global Opportunities Liquid Portfolio Sub-Master LP (1)(2)(3)
Date:	07/01/2025

HALVORSEN OLE ANDREAS

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of HALVORSEN OLE ANDREAS (1)
Date:	07/01/2025

Ott David C.

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Ott David C. (2)
Date:	07/01/2025

Shabet Rose Sharon

Signature:	/s/ Scott M. Hendler
Name/Title:	Scott M. Hendler on behalf of Shabet Rose Sharon (3)
Date:	07/01/2025

Comments accompanying signature:

(1) Scott M. Hendler is signing on behalf of O. Andreas Halvorsen, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (2) Scott M. Hendler is signing on behalf of David C. Ott, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737). (3) Scott M. Hendler is signing on behalf of Rose S. Shabet, individually and as an Executive Committee Member of VIKING GLOBAL PARTNERS LLC, on behalf of VIKING GLOBAL INVESTORS LP, and as an Executive Committee Member of VIKING GLOBAL PERFORMANCE LLC, on behalf of itself and VIKING GLOBAL EQUITIES II LP and VIKING GLOBAL EQUITIES MASTER LTD., and as an Executive Committee Member of VIKING LONG FUND GP LLC, on behalf of itself and VIKING LONG FUND MASTER LTD., and as an Executive Committee Member of VIKING GLOBAL OPPORTUNITIES PARENT GP LLC, on behalf of itself and VIKING GLOBAL OPPORTUNITIES GP LLC, VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC, VIKING GLOBAL OPPORTUNITIES ILLIQUID INVESTMENTS SUB-MASTER LP, and VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP, pursuant to an authorization and designation letter dated February 9, 2021, which was previously filed with the Commission as an exhibit to a Form 13G filed by Mr. Halvorsen on February 12, 2021 (SEC File No. 005-49737).

FAQ

How many BridgeBio (BBIO) shares did Viking Global sell on 06/27/2025?

The filing reports the sale of 3,500,000 common shares.

At what price were the BBIO shares sold by Viking Global?

The shares were disposed of at an indicated price of $44.00 per share.

What is Viking Global's remaining BBIO stake after the sale?

Viking entities now beneficially own 18,555,375 shares of BridgeBio Pharma.

Does Viking Global remain a 10% owner of BridgeBio after the transaction?

Yes. Despite the sale, the group still exceeds the 10 % ownership threshold.

Were any derivative securities involved in this Form 4 filing?

No. The filing lists no derivative acquisitions or dispositions.

Who are the individuals deemed beneficial owners in the filing?

Executive committee members Andreas Halvorsen, David C. Ott and Rose S. Shabet are listed as indirect beneficial owners.